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ABSTRACT  
A hepatitis C virus (HCV) epidemic affecting HIV-infected men who have sex 
with men (MSM) is expanding worldwide. In spite of the improved cure 
rates obtained with the new direct-acting antiviral drug (DAA) combinations, 
the high rate of reinfection within this population calls urgently for novel 
preventive interventions. In this study, we determined in cell culture and ex 
vivo experiments with human colorectal tissue that lipoquads, G-quadruplex 
DNA structures fused to cholesterol, are efficient HCV pangenotypic entry 
and cell-to-cell transmission inhibitors. Thus, lipoquads may be promising 
candidates for the development of rectally applied gels to prevent HCV 
transmission. 
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Hepatitis C virus (HCV) infection of human immunodeficiency virus 
(HIV)-infected men who have sex with men (MSM) has emerged since the 
early 2000s as a growing epidemic worldwide (1). Although the introduction 
of interferon-free direct acting antiviral (DAA) therapies improved 
significantly the sustained treatment responses, the rates of reinfection 
after treatment termination among HIV- and HCV-coinfected MSM are high 
(2, 3). Consequently, preventive interventions tailored to the MSM 
community are urgently needed. Given that this HCV epidemic is linked to 
high-risk sexual behaviors that include unprotected anal sex, formulations 
of water-soluble molecules as rectally applied gels that prevent HCV 
transmission would represent an ideal option. Currently, there are no 
prophylactic therapies for HCV in this setting. 
G-quadruplexes comprise a distinct category of nucleic acid 
secondary structures that are formed from G-rich DNA and RNA sequences 
(4). Polymorphisms in these structures can be observed in the number 
(from one to four) and orientation of the strands, the number of stacked G-
tetrads, differences in the loop (length, type, and/or location), and, finally, 
the dimension of the four grooves (4). The guanosine quartet AR177 
(Zintevir, Aronex Pharmaceuticals, Inc.) is a 17-base oligonucleotide 
composed of deoxyguanosines and thymidines on a phosphodiester 
backbone supplemented by phosphorothioate internucleoside linkages at 
the 5’ and 3’ ends. AR177 is a potent inhibitor of laboratory strains and 
clinical isolates of HIV-1, with 50% effective concentrations (EC50) ranging 
between 0.025 and 3 M in cell culture tests (5, 6). The effect is an 
inhibition of viral entry by blocking a step before membrane fusion, and 
virus-resistant strains have shown mutations in the HIV gp120 gene (7). 
Similar G/T-rich phosphorothioate oligonucleotides have been reported to 
have antiviral activity against herpes simplex virus 2 (8). G-quadruplexes 
are polyanionic structures like sulfated polysaccharides, and hence, their 
inhibition mechanism may include mimetics of the glycosaminoglycans 
(GAGs) and other cell surface attachment receptors involved in virus-cell 
attachment. Thus, these molecules compete with viral envelope 
glycoproteins during binding with their main receptors. 
HCV cell-free virions enter into hepatocytes through a highly 
coordinated process which involves the two viral envelope glycoproteins E1 
and E2 and multiple host cell factors. HCV first associates with its target 
cells through interactions of basic residues in its glycoproteins with GAGs, 
including heparan sulfate proteoglycans (HSPG) (9–11). Apolipoprotein E 
(ApoE), which associates with HCV virions, also plays a role in the initial 
attachment through interaction with the HSPG associated with syndecan 1 
(SDC1) (12) and syndecan 4 (SDC4) (13). The liver/lymph node-specific 
intercellular adhesion molecule 3-grabbing integrin (L-SIGN) (14, 15) and 
the low-density lipoprotein receptor (LDLR) (16, 17) have been also 
implicated in the preliminary attachment of cell-free viruses. Although the 
exact sequential order of receptor engagement is still unclear, some 
evidence suggest that HCV virions interact with scavenger receptor class B 
type 1 (SR-B1), CD81, tight junction proteins claudin-1 (CLDN1), occludin 
(OCLN), and possibly other factors (18). Virions are later internalized 
through clathrin-mediated endocytosis and fuse with the host membrane 
following endosomal acidification (19). Finally, the transferrin receptor 1 
(TfR1) (20), epidermal growth factor receptor (EGFR) and ephrin receptor 
A2 (EphA2) (21), and Niemann-Pick C1-like 1 cholesterol absorption 
receptor (NPC1L1) (22) have also been implicated in HCV entry. Cell-to-cell 
spread has been also presented as an important route for HCV transmission 
within the infected liver. The requirements for this alternative route suggest 
that SR-B1, CLDN1, OCLN (23), EGFR, EphA2 (21), and NPC1L1 (24) are 
implicated for both cell-free and cell-to-cell spread. 
In the present study, we characterized the anti-HCV inhibitory 
capacity of novel lipid-G-quadruplex conjugate structures, designated 
lipoquads (Fig. 1A). First, we showed that the anti-HCV potency of 
lipoquads is correlated with the ability of the G-rich sequences to form 
stable structures. Then, by using the HCV pseudoparticles (HCVpp), which 
are a well-established system to investigate HCV entry and neutralization 
(25, 26) and cell culture-produced viruses (HCVcc), we characterized the 
inhibition mechanism of lipoquads acting at the early steps of HCV entry, 
including the attachment phase, and demonstrated that this inhibition is 
linked to basic amino acids in hypervariable region 1 (HVR1) of the E2 
glycoprotein and/or to HVR1 itself. Moreover, lipoquads also inhibit cell-to-
cell HCV transmission and potently inhibit all major HCV genotypes. Finally, 
we provide evidence that lipoquads inhibit HCV infection ex vivo in a 
mucosal model based on colorectal tissue explants. Our results pave the 
way for the use of lipoquads in the development of prevention strategies 
against HCV. 
 
RESULTS 
Lipoquads inhibit HCVcc infection. To evaluate the inhibitory 
effects of lipoquads (Fig. 1A) on HCV infection, we used the HCVcc system 
(27–29). Unless otherwise stated, we used the highly permissive Huh7/Scr 
cells (30) for HCV propagation in vitro. Furthermore, we used the highly 
infectious genotype 2a HCVcc virus (Jc1 chimera [31]). To simplify the 
quantification of infection, we used the bicistronic Jc1 luciferase reporter 
construct designated Luc-Jc1 HCVcc (10). Cell viability was monitored in 
parallel by a commercial ATP assay (32). Briefly, cells were preincubated for 
1 h at 37°C with lipoquads and then inoculated with the virus in the 
presence of lipoquads for 4 h at 37°C. After this, virus-containing medium 
was replaced with a fresh medium lipoquad mixture. Luciferase activity was 
assayed 72 h postinfection. As shown in Fig. 1B, Luc-Jc1 HCVcc infection of 
Huh7/Scr cells was completely inhibited by lipoquads at concentrations in 
the 5 to 10 M range (maximum percent inhibition [MPI]) without affecting 
cell viability. The half-maximal inhibitory concentration (IC50) for lipoquads 
was estimated to be 0.8 M, with a half-maximal cytotoxic concentration 
(CC50) was above 10 M. Under the same infection conditions, dasatinib (21), 
an FDA-approved anticancer kinase inhibitor which has been shown to 
inhibit HCV entry, inhibited HCV with an IC50 of 3.2 M and a CC50 of 51.8 
M. Disruption of the G-quadruplex structure by exchanging three of the 
guanines with adenines resulted in an 7.8-fold increase of the IC50 (Fig. 
1C), indicating a certain specificity mediated by the G-quadruplex element. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 1 Quadruplex DNA structures (lipoquads) are potent HCV inhibitors. (A) 
Sequence and schematic structure of the parallel tetramolecular lipoquads 
of the present study, formed by the association of four 17-mer 
oligonucleotides containing the GGGGGG (orange) repeat. The structure is 
held by six stacked G-quartets. The 3’ extremities of the individual strands 
are conjugated with a cholesteryl function (magenta), forming a lipophilic 
tail. (B) Anti-HCV activity of lipoquads and viability of Huh7/Scr cells 
infected with Luc-Jc1 HCVcc viruses (at an MOI of 0.01 to 0.03 TCID50/cell) 
and treated with increasing concentrations of lipoquads or dasatinib 
(positive control). (C) Anti-HCV activity and viability on Huh7/Scr cells 
infected with Luc-Jc1 HCVcc viruses and treated with increasing 
concentrations of lipoquads or A-rich control sequence. Infectivity and 
viability were determined 72 h postinfection by luciferase assays. Results 
are the means (±SEM) from two replicate infections measured in duplicates 
and expressed as RLU compared to the infection of control (mock) cells. The 
data presented are from a single experiment and are representative of 
those from three independent experiments. 
 
 
 
 
FIG 2 Lipoquads preferentially inhibit HCV pseudoparticles (HCVpp). 
Huh7/Scr cells were pretreated for 1 h with 5 M lipoquads or dasatinib. 
Then cells were inoculated with HCVpp or VSV-Gpp in the presence of 
compounds. Six hours later, the medium was replaced with a fresh 
medium-compound mixture. Infectivity and viability were determined 72 h 
postinfection by Renilla luciferase for infectivity (A) or Firefly luciferase 
assays for cell viability (B). Results are the means (±SEM) from two 
replicate infections measured in duplicate and expressed as RLU compared 
to the infection of control (lipoquads solvent for lipoquads or DMSO for 
dasatinib) cells for both infectivity and viability. The data presented are 
from a single experiment and are representative of those from three 
independent experiments. 
 
 
Lipoquads inhibit the infection of HCVpp. To examine if lipoquads 
inhibit HCV entry, we used HCVpp that carried the same E1E2 glycoproteins 
as Luc-Jc1 HCVcc. HCVpp are a well-established system to investigate HCV 
entry and neutralization (25, 26). HCVpp infection conditions with lipoquads 
were similar to those used with Luc-Jc1 HCVcc, except that Huh7/Scr cells 
were inoculated with HCVpp for 6 h. Dasatinib was used again as a positive 
control. At a 5 M concentration, which has been shown previously to inhibit 
Luc-Jc1 HCVcc infection potently, lipoquads inhibited HCVpp entry 8-fold, 
while pseudoparticles carrying the vesicular stomatitis virus glycoprotein 
(VSV-Gpp) were inhibited only 2-fold (Fig. 2A). Thus, lipoquads inhibit 
E1E2-mediated HCV entry into target cells with a preference over the VSV-G 
envelope.  
 
Lipoquads interact with HCV and inhibit early entry steps of 
HCV life cycle. To identify which HCV entry step was inhibited, we carried 
out time-of-addition experiments using Luc-Jc1 HCVcc viruses. To this end, 
we carried out 4 different incubation protocols (Fig. 3A): (i) Huh7/Scr cells 
were preincubated with lipoquads for 1 h prior to inoculation, (ii) Luc-Jc1 
HCVcc viruses were preincubated for 1 h with lipoquads prior to inoculation 
and then viruses containing lipoquads were added to the cells, (iii) 
lipoquads were present only during infection for 4 h, or (iv) lipoquads were 
added to cells postinoculation (from 4 h until the time of the luciferase 
assays). As shown in Fig. 3B, lipoquads inhibited Luc-Jc1 HCVcc infection 
only when they were preincubated with Luc-Jc1 HCVcc viruses or added 
simultaneously to the cell-virus mixture, indicating that lipoquads act on the 
viral particles and/or initial steps of HCV entry. Further, in order to test if 
lipoquads inhibits HCV attachment on the surface of target cells, Huh7/Scr 
cells were incubated with Jc1 HCVcc without reporters in the presence or 
absence of inhibitors for 2 h at 4°C. Under these conditions, virus attaches 
to the cells but does not efficiently enter. Heparin sodium salt, which is 
known to inhibit HCV entry at the attachment step, was used as a positive 
control (10). After 2 h, viruses were removed, cells were washed 
extensively to remove the unbound virus, and the bound HCV was 
quantified with quantitative reverse transcription-PCR (qRT-PCR). As shown 
in Fig. 4, lipoquads efficiently inhibited HCV attachment, indicating a role at 
least in early entry steps. 
 
 
 
FIG 3 Lipoquads interact with HCV particles and selectively inhibit early 
HCV entry events. Huh7/Scr cells were inoculated with Luc-Jc1 HCVcc 
viruses (at an MOI of 0.01 to 0.03 TCID50/cell) prepared in the absence of 
drugs. Lipoquads (final concentration, 1 M) were added to the cells only 
before inoculation for 1 h (black), preincubated with the viruses (hatched), 
only during inoculation (gray), or selectively after infection (white), as 
schematically depicted in panel A. Infectivity and viability (B) were 
determined 72 h later by Firefly luciferase assays. Results are the means 
(±SEM) from two replicate infections measured in duplicate and expressed 
as RLU compared to the infection of control (mock) cells. The data are from 
a single experiment and are representative of those from three independent 
experiments. ns, not significant. 
 
 
Lipoquads inhibit neither HCV RNA translation nor HCV RNA 
replication. To test whether lipoquads exert an additional effect on HCV 
translation and/or replication, we transfected Huh7/Scr cells with a 
subgenomic JFH1 luciferase replicon (SGR-JFH1). Lipoquads were present 
for a preincubation period of 1 h, during transfection (4 h), and 
posttransfection, as described previously for Luc-Jc1 HCVcc infections. RNA 
replication was monitored 24 h posttransfection by luciferase assays. As a 
control, we incubated the cells with increasing doses of the NS3-4A 
protease inhibitor telaprevir (VX-950). As shown in Fig. 5, lipoquads did not 
affect luciferase expression, while telaprevir showed a sharp reduction in 
luciferase expression, indicating that lipoquads do not inhibit HCV RNA 
translation and/or replication.  
 
Basic residues of HVR1 and HVR1 itself play a role in lipoquad-
mediated HCV neutralization. Hypervariable region 1 (HVR1) of the HCV 
E2 glycoprotein is known to facilitate virus-host cell interactions (33). To 
investigate whether this region is involved in the lipoquad-mediated HCV 
inhibition, we performed inhibition experiments with HCV mutants carrying 
altered HVR1 regions (Fig. 6). To this end, we used Luc-Jc1 wild-type (WT) 
HCVcc viruses, Luc-Jc1 HCVcc viruses which harbor a total deletion of the 
HVR1 region (ΔHVR1 [34]), or a Luc-Jc1 HCVcc virus mutant that possesses 
alanines instead of the basic amino acids in HVR1 (basic- [77]). In order to 
observe subtle differences in lipoquad inhibition, we used a 1 M final 
concentration in this setting, which according to Fig. 1 is higher than the 
IC50 but below 100% inhibition. As shown in Fig. 6, WT virus was inhibited 
up to 80%, while both mutants (ΔHVR1 and basic-) were not affected. This 
suggests a direct role of the basic amino acids of the HVR1 and/or of the 
HVR1 region itself in lipoquad antiviral activity. 
 
 
 
FIG 4 Lipoquads block virus attachment to the cell. Huh7/Scr cells were 
placed on ice for 30 min to cool down. Cells were then incubated for 2 h 
with prechilled Jc1 HCVcc (MOI, 10 TCID50s/cell) at 4°C. Lipoquads (5 M), 
heparin (100 g/ml), or buffer (mock) was added to the cells 
simultaneously with virus inoculation. Cell monolayers were washed 3 times 
with cold PBS and then lysed and subjected to RNA extraction. HCV RNA 
was quantified by qRT-PCR in 25 ng of total RNA. Results are the means 
(±SEM) from two replicate infections measured in triplicate and expressed 
as relative RNA compared to the viral attachment of control (mock) cells. 
The data are from a single experiment and are representative of those from 
three independent experiments. 
 
 
Lipoquads inhibit HCV cell-to-cell transmission. To assess 
whether lipoquads can inhibit HCV cell-to-cell transmission, we used an 
agarose overlay-based assay which inhibits cell-free virus, using a 
previously described infection reporter system (35). In this infection 
reporter system, Jc1 HCVcc-infected Huh7/Scr cells act as virus donor cells 
and uninfected Huh7.5/EGFP-NLS-IPS as acceptor cells (35, 36). The latter 
cells stably express a chimeric enhanced green fluorescent protein (EGFP) 
which upon HCV infection is redistributed from mitochondria to the nucleus 
(a complete description of these cells is available in Materials and Methods). 
Moreover, HCV infection was evaluated by anti-NS5A immunofluorescence. 
For consistency with the previous experiments, the lipoquad incubation 
period was similar to that used for cell-free infections. As shown in Fig. 7, 
lipoquads and the control dasatinib efficiently inhibited HCV cell-to-cell 
transmission, as deduced by the number of NS5A-positive acceptor cells 
and EGFP redistribution to the nucleus. 
 
 
 
 
FIG 5 Lipoquads do not inhibit HCV subgenomic replicons. Huh7/Scr cells 
were pretreated with lipoquads or telaprevir (VX-950) at increasing 
concentrations (0.004, 0.016, 0.08, 0.4, 2, and 10 M) for 1 h, transfected 
with SGR RNA (compounds present), and seeded in 96-well plates. Four 
hours posttransfection, Lipofectamine-RNA-containing medium was replaced 
with a fresh medium-compound mixture, and Firefly luciferase activity was 
assayed 24 h later. In both panels A and B, results are the means (±SEM) 
from two replicate transfections measured in duplicate and expressed as 
RLU compared to the transfection of control (mock) cells for both infectivity 
and viability. The data are from a single experiment and are representative 
of those from three independent experiments. 
 
 
 
FIG 6 Basic amino acids in E2 HVR1 and HVR1 itself play a role in lipoquad-
mediated HCV inhibition. Huh7/Scr cells were inoculated with Luc-Jc1 WT 
HCVcc viruses or with the indicated mutants (at an MOI of 0.01 to 0.03 
TCID50/cell). Lipoquads (final concentration, 1 M) were added to the cells 
simultaneously with inoculation. The HCVcc-compound mixture was 
replaced 4 h postinfection with a fresh mediumcompound mixture, and 72 h 
after infection, cells were assayed for Firefly luciferase activity. Results are 
the means (±SEM) from two replicate infections measured in duplicate 
(black bars) and expressed as RLU compared to the infection of control 
(mock) cells (white bars) for both infectivity (A) and viability (B). The data 
are from a single experiment and are representative of those from three 
independent experiments. 
 
 
Lipoquads inhibit entry of all major HCV genotypes. To 
determine the antiviral efficiency of lipoquads against all major HCV 
genotypes, we utilized JFH1-based reporter virus constructs (JFH1 NS3-
NS5B proteins) carrying Renilla luciferase inserted at the NS5A gene and 
core to NS2 proteins from all major HCV genotypes: 1a (isolate TN), 1b 
(isolate J4), 2b (isolate J8), 3a (isolate S52), 4a (isolate ED43), 5a (isolate 
SA13), 6a (isolate HK6a), and 7a (isolate QC69) (37). Strikingly, lipoquads 
showed antiviral activity against all major HCV genotypes (Fig. 8). The 
estimated IC50 for each HCV genotype (Table 1) was comparable to the IC50 
estimated in the first set of experiments for the genotype 2a Luc-Jc1 HCVcc. 
 
Lipoquads inhibit HCV ex vivo in a mucosal model. To assess 
lipoquad activity ex vivo, we tested lipoquads in a mucosal model based on 
ex vivo viral challenge of colorectal tissue explants (38, 39). This model 
allowed us to evaluate the potency of lipoquads as an HCV entry inhibitor 
against a reporter HCV, Jc1FLAG(p7-nsGluc2A), by measurement of Gaussia 
luciferase expressed and secreted upon viral entry, translation, and/or 
replication of the HCV genome (40). Pulse exposure of explants to drug for 
3 h resulted in a dose-dependent reduction of viral levels (Fig. 9A) (IC50 of 
11.88 ± 7.35 M). Interestingly, the level of inhibition reached with the 
highest drug concentration tested was similar to that obtained with a 
combination of sofosbuvir (SOF) and ledipasvir (LDV) (both at a 1 M final 
concentration). With sustained exposure to lipoquads (compound 
maintained throughout explant exposure to virus and culture), a decrease in 
the IC50 to 1.08 ± 0.13 M and an increase in Jc1FLAG(p7-nsGluc2A) 
infection inhibition up to 93% were reached within the concentration range 
tested (Fig. 9B). Together, these data demonstrate the potential of 
lipoquads as candidate drugs for topical HCV prevention strategies. 
 
 
DISCUSSION 
 
The introduction of DAA therapies in the standard-of-care (SoC) treatment 
of HCV has increased significantly the sustained virological response (SVR) 
rates, accompanied by manageable adverse effects (41). However, these 
compounds target one of the nonstructural proteins of HCV (NS3-4A, NS5A, 
and/or NS5B) and thus cannot prevent HCV infection. Here, we report a 
class of novel oligonucleotide-lipid conjugates forming G-quadruplex 
structures, designated lipoquads, as potent and pangenotypic HCV entry 
inhibitors in vitro. Moreover, we were able to show anti-HCV activity ex vivo 
in an intestinal mucosa explant model, using genotype 2a HCVcc. Notably, 
lipoquads exhibited IC50s comparable to those of known FDA-approved 
drugs like dasatinib and telaprevir (VX-950). In addition, lipoquads were 
able to achieve an MPI at 5 to 10 M. These data for lipoquads as antiviral 
compounds are important if breakthrough and/or resistance needs to be 
tested. With their absence of toxicity at the concentrations tested and their 
high water solubility, lipoquads present attractive candidates for the 
development of HCV prevention strategies. 
 
 
 
FIG 7 Lipoquads inhibit HCV cell-to-cell transmission. Huh7/Scr cells were 
infected with Jc1 HCVcc at an MOI of 10 TCID50/cell and 20 h later seeded 
on 24-well plates. Simultaneously, Huh7.5/EGFP-NLS-IPS cells were seeded 
on the same 24-well plates (coculture, at a ratio 1:1 with Huh7/Scr cells), 
and lipoquads (10 M) or dasatinib (10 M) was added to the wells. The 
addition of the compound solvent (lipoquad solvent or DMSO) served as a 
negative control. Four hours later, medium was removed and cells were 
overlaid with 1% agarose with fresh compounds. Twenty-four hours later, 
the HCV infection was analyzed by immunofluorescent NS5A staining. (A) 
Results are the means of quantification of Huh7.5/EGFP-NLS-IPS cells in 3 
independent wells by taking 3 independent pictures of different fields of 
each well that contained at least 200 cells in total. Cell-to-cell inhibition is 
expressed as the percentage of acceptor cells with the EGFP-NLS plus NS5A 
signal with respect to the total number of EGFP plus NS5A cells in the 
DMSO-treated (for dasatinib) or lipoquad buffer-treated (for lipoquads) 
wells. (B) Representative images of coculture cells stained with anti-NS5A 
antibodies. Huh7.5/EGFP-NLS-IPS cells with EGFP signal redistributed to the 
nucleus and cytoplasmatic NS5A signal are indicated with arrows. 
Magnification, x63. 
 
 
 
FIG 8 Lipoquads inhibit HCV isolates of different genotypes. Huh7/Scr cells 
were inoculated with viruses of the indicated genotypes and isolates (at an 
MOI of 0.01 to 0.03 TCID50/cell). Lipoquads at the indicated concentrations 
were added to the cells simultaneously with inoculation. The HCVcc-
compound mixture was replaced 4 h postinfection with a fresh medium-
compound mixture. Seventy-two hours postinfection, cells were assayed for 
Renilla luciferase activity for infectivity (A) or Firefly luciferase for cell 
viability (B). Results are the means (±SEM) from two replicate infections 
measured in duplicate and expressed as RLU compared to the infection of 
control (mock) cells. The data are from a single experiment and are 
representative of those from three independent experiments. 
 
 
To characterize the lipoquads’ inhibition mechanism, we used several 
molecular tools in diverse infection assays. First, we used the HCVpp system 
in order to isolate the entry process from other HCV functions, i.e., 
replication/translation and assembly/ release. Because lipoquads inhibited 
HCVpp and had no effect on the subgenomic replicon, we conclude that 
lipoquads target viral entry. HCV entry is a complex process that requires 
several entry molecules (see references 42 and 43 for reviews). It 
comprises the steps from particle binding to the host cell up to the delivery 
of the viral genome to the replication site within the cell. Initial binding is 
mediated by interactions between HCV E1E2 envelope glycoproteins and 
glycosaminoglycans (GAGs) (11). Also, LDLRs on host cells may function as 
initial attachment factors due to the association of HCV with LDL or very-
low-density lipoprotein (16, 17). Following this initial engagement, 
tetraspanin CD81 and SR-B1 together with the tight junction proteins 
CLDN1 and OCLN are the main receptors contributing to HCV uptake (44–
47). Our results show that lipoquads inhibit HCV infection by negatively 
affecting virus-cell binding. This effect is presumably mediated via direct 
interaction of the compound with the virus, since preexposure of the cells to 
lipoquads did not result in decreased infectivity. Lipoquads are therefore 
responsible for blocking the interaction of the virus with the cellular 
receptors. 
To shed more light onto the mechanism of interaction between 
lipoquads and HCV, we used two HCV mutants for the E2 HVR1, one in 
which all basic amino acids of the region were replaced by alanines (basic-) 
and one that lacked the region itself (ΔHVR1). Importantly, neither of them 
was inhibited by lipoquads. Although HVR1 is not essential for HCV 
productive infection, viruses lacking this domain are less infectious, both in 
vitro (48) and in vivo (34). HVR1 displays high genetic variability between 
HCV isolates, which likely contributes to immune evasion of HCV. Previous 
experiments performed with HVR1 deletion mutants suggest that HVR1 may 
act as immunological decoy since it shields conserved neutralizing epitopes 
(48). Indeed, ΔHVR1 mutants show increased neutralization susceptibility to 
HCV patient sera (48, 49). It has been proposed that a complex interplay 
between several regions of E2 is responsible for modulating receptor 
binding, possibly through intramolecular interactions (50). As deduced from 
our results, lipoquads may affect this interplay. Particularly, lipoquads 
display negative charges, so a positive-negative electrostatic interaction is 
likely to occur. Furthermore, alignment of the HVR1 domains of the different 
HCV genotypes reveals a conserved presence of positively charged residues 
(data not shown). Thus, HCV pangenotypic activity of lipoquads can also be 
explained by the interaction with basic amino acids in the E2 glycoprotein. 
Overall, although conclusive evidence for the target of lipoquads is lacking, 
we hypothesize that lipoquads use a common mechanism that involves 
electrostatic interactions with positively charged residues in viral entry 
proteins. 
 
TABLE 1 Antiviral activity (IC50) of lipoquads across all major HCV 
genotypes 
 
HCV genotype IC50 (M) 
1a (TN) 0.9 
1b (J4) 0.2 
2b (J8) 0.3 
3a (S52) 0.3 
4a (ED43) 0.9 
5a (SA13) 1.2 
6a (HK6a) 1.5 
7a (QC69) 0.5 
 
 
 
 
FIG 9 Inhibitory activity of lipoquads in colorectal tissue explants against 
HCVcc Jc1FLAG(p7-nsGluc2A). Mucosal explants were treated for 1 h in the 
presence or absence of lipoquads (at the indicated concentrations) or SOF-
LDV (both at a 1 M final concentration) prior to viral exposure for 2 h (total 
compound presence, 3 h). Explants were then washed four times with PBS 
and transferred to gel foam rafts. Tissue explants were kept in culture for 
48 h in the absence (pulse) (A) or in the sustained presence of compounds 
(B). Culture supernatants were harvested for detection of Gaussia luciferase 
activity, and the extent of infection was plotted as a percentage relative to 
the RLU obtained for explants infected with virus in the absence of 
compound (100% infectivity). Data represent the means (±SEM) of three 
independent experiments performed in triplicate. 
 
 
 
HCV entry into target hepatocytes, as cell-free virus, has been proven 
to be a well-orchestrated process with spatiotemporal requirements. 
Notably, in addition to infection by cell-free virus, direct cell-to-cell 
transmission also occurs in the liver (51) and in cultured hepatocytes (53–
57). This route of viral spread may provide a way to avoid neutralization, 
resulting in viral persistence and hampering viral eradication (57). DAA-
resistant variants have been shown to use cell-to-cell transmission as the 
main route of viral spread in cell culture (58). Hence, lipoquads possess a 
great additional value owing to their cell-to-cell virus transmission inhibition 
capacity. Most host entry factors are shared between the two routes. These 
include SR-B1, CLDN1, OCLN, and NPC1L1 as well as EGFR and its signal 
transducer HRas (21, 24, 59–61). The dependence on CD81 in cell-to-cell 
transmission remains controversial (23, 62). While the role of these factors 
during HCV cell-free transmission has been extensively studied, mechanistic 
insights about their spatiotemporal role during HCV cell-to-cell spread are 
still far from being satisfactory. Thus, although lipoquads appear to inhibit 
initial HCV cell-free attachment and therefore interfere with the interaction 
of HCV with attachment molecules/receptors, the exact mechanism of HCV 
cell-to-cell inhibition by lipoquads needs further investigation. Importantly, 
the majority of monoclonal antibodies targeting the viral envelope have 
been shown to fail to inhibit cell-to-cell transmission. In contrast, several 
host-targeting entry inhibitors (HTEIs) have succeeded in blocking this 
route of viral spread (21, 59). Since lipoquads target directly the viral 
particles and do not interfere with cellular processes, they present a 
significant advantage against HTEIs.  
Antivirals formulated for topical applications are known as 
microbicides, and viral entry into the target cell represents an important 
point where microbicides can inhibit mucosal transmission. In more detail, 
the intestinal mucosa is composed of intestinal epithelial cells (enterocytes, 
secretory cells, and intestinal epithelial stem cells), stromal cells, and 
myofibroblasts. Colorectal tissue also contains T cells, B cells, dendritic 
cells, macrophages, and innate lymphoid cells in the lamina propia (63, 64). 
Furthermore, the expression of certain HCV entry receptors in the intestinal 
mucosa has been described previously (65–69). These cells could be the 
primary target cells for virus infection through mucosal transmission. In the 
field of HIV prevention, proof of concept that microbicides can block HIV 
transmission was obtained in a clinical efficacy trial (70), although 
ultimately, the efficacy of any microbicide product depends upon adherence 
as well as appropriate drug delivery (71). Microbicides are topical antivirals, 
and therefore, their inhibitory activity needs to be considered within the 
context of mucosal transmission. Mucosal tissue explant models are 
becoming an essential tool for preclinical screening of candidates for oral 
and topical preexposure prophylaxis against HIV (39) and are increasingly 
being used in HIV prevention clinical trials (72–75). In this study, we 
expanded the usage of this mucosal model to assess the inhibitory potency 
of lipoquads against HCV. Our results are important because they clearly 
show HCV transmission through the mucosa, although HCV primarily infects 
and replicates in hepatocytes. Nevertheless, we were able to inhibit HCV 
intestinal mucosa infection by DAA, suggesting that HCV replicates in this 
ex vivo model as well. Furthermore, pulse exposure of the tissue to 
lipoquads showed limited potency, reaching a maximum of 55% of 
inhibition; however, sustained exposure showed a significant increase of 
activity, with a decrease in the IC50 and an increase in the level of inhibition 
reached at the highest concentration tested. Because microbicides are 
topically applied, higher local drug concentrations can be delivered to 
mucosal surfaces without significant systemic exposure, thereby reducing 
the risk of long-term toxicity in healthy but at-risk individuals. 
In conclusion, permucosal HCV transmission has been confirmed as 
the most likely mode of HCV infection in MSM and has become a significant 
source of new HCV infections. In essence, HCV sexual transmission 
concerns the general population, independently of sexual preferences. This 
calls for new antiviral drugs that permit an efficient topical preexposure 
prophylaxis. Our work in this study demonstrates that lipoquads are 
efficient pangenotypic HCV entry inhibitors with interesting properties that 
make them candidates for further studies on drug formulations and dosing 
evaluations. Providing safe and acceptable microbicides to the community at 
risk to sexually acquire HCV will be an important step in HCV transmission 
control. Lipoquad presents itself as a candidate compound for development 
in this direction. 
 
 
MATERIALS AND METHODS 
 
Oligonucleotide synthesis and G-quadruplex preparation. 
Oligonucleotide sequences 5’-TTG GGGGGTACAGTGCA-3’-cholesterol and 
the A-rich control sequence 5’-TTGAAAGGTACAGTGCA-3’-cholesterol were 
assembled using an automatic oligonucleotide synthesizer (Applied 
Biosystems 3400; Applied Biosystems, Foster City, CA). The solid support 
functionalized with cholesterol and the rest of the chemicals were from 
commercial sources (Link Technologies, Scotland, UK). After the assembly 
of the sequences, supports were treated with ammonia and the desired 
oligonucleotides were purified by reverse-phase high-performance liquid 
chromatography (HPLC). The oligonucleotides were next suspended at a 
concentration of 1.6 mM in an annealing buffer (lipoquad solvent, 20 mM 
Tris acetate [pH 7.0], and 50 mM potassium acetate), boiled for 5 min at 
95°C, slowly cooled down to room temperature, and incubated at 25°C for 
at least 14 days. G-quadruplex formation was followed by 10% 
nondenaturing polyacrylamide gel electrophoresis as described previously 
(76) and verified by circular dichroism. The compounds were stored at -
20°C until use. 
 
Cell culture. The human hepatocarcinoma cell lines Huh7/Scr and 
Huh7.5.1 Cl.2 (kindly provided by F. Chisari) and the human embryonic 
kidney cell line 293T (HEK293T cells; American Type Culture Collection, 
Manassas, VA; CRL-1573) were maintained in Dulbecco’s modified Eagle 
medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum, 10% nonessential amino acids, 100 U/ml of penicillin, and 
100 U/ml of streptomycin. Cells were grown in an incubator with 5% CO2 at 
37°C. 
 
Plasmids. (i) Plasmids used to produce HCVcc. Plasmid pFK-Jc1 has 
been described previously (31). It encodes a chimeric HCV consisting of 
codons 1 to 846 derived from J6/CF (genotype 2a; GenBank accession 
number AF177036) combined with codons 847 to 3033 of JFH1 (genotype 
2a; GenBank accession number AB047639). Plasmid pFK-Luc-Jc1 (27) 
consists of a bicistronic construct in which the HCV polyprotein-coding 
region is located in the second cistron and is expressed via an internal 
ribosome entry site (IRES) element derived from encephalomyocarditis 
virus (EMCV), while the first cistron contains the Firefly luciferase reporter 
gene. Plasmids encoding the HVR1 mutants are also based on the Jc1 
genome and have been described elsewhere (77). Briefly, these plasmids 
are pFK-Luc-Jc1 derivatives. The pFK-Luc-Jc1-ΔHVR1 plasmid encodes a 27-
amino-acid deletion of the E2 HVR1 region, while the pFKLuc- Jc1-basic 
plasmid possesses an alanine substitution in all basic amino acids of the 
HVR1 (basic-mutant). HCV genotype 1 to 7 plasmids are JFH1-based 
reporter virus constructs (NS3 to NS5B of JFH1 origin; genotype 2a), 
carrying Renilla luciferase inserted at the NS5A gene and expressing core 
nonstructural protein 2 (NS2) of genotype 1 to 7 prototype isolates (37). 
HCV Jc1FLAG(p7-nsGluc2A) is a cell culture-derived virus chimera of J6 and 
JFH1 (genotype 2a/genotype 2a chimera), which is fully infectious and 
carries the Gaussia luciferase gene as a reporter gene (40). 
(ii) Plasmid used to produce HCV subgenomic replicon. The 
subgenomic replicon plasmid carries a bicistronic construct in which a Firefly 
luciferase gene is expressed via HCV IRES and an EMCV IRES drives 
expression of JFH1 nonstructural proteins (NS3 to NS5B) (78). 
(iii) Plasmids used to produce HCVpp. Plasmid pTN7-Stopp 
(kindly provided by M. Dittmar) carries the HIV-1 genome with the following 
modifications: the Renilla luciferase reporter gene has replaced the nef 
gene, and the plasmid lacks a functional env gene (79). The plasmid, which 
encodes strain HC-J6CH E1E2 glycoproteins and is designated pcDNA3.1-
ΔcE1E2-J6CH, has been described elsewhere (77). Plasmid pVPack-VSV-G, 
which encodes the vesicular stomatitis virus glycoprotein (VSV-G), has been 
purchased by Agilent Technologies (Santa Clara, CA). 
In vitro transcription, electroporation, and preparation of 
virus stocks. Plasmids carrying Jc1 constructs were linearized with the 
MluI enzyme, while plasmids carrying genotype 1-7/JFH1 chimeric viruses 
and the Gaussia reporter were linearized with the XbaI enzyme. Plasmid 
DNA was purified with a QIAquick PCR purification kit (Qiagen, Düsseldorf, 
Germany). Purified DNA was subjected to an in vitro transcription reaction 
with a MEGAscript T7 kit (Applied Biosystems, Foster City, CA) according to 
the manufacturer’s protocol. RNA from the in vitro transcription reaction 
was purified with a Nucleospin RNA II kit (Macherey-Nagel, Düren, 
Germany), RNA integrity was verified by formaldehyde agarose gel 
electrophoresis, and the concentration was determined by measurement of 
the optical density at 260 nm. For RNA electroporations, single cell 
suspensions of Huh7.5.1 Cl.2 cells were prepared by trypsinization of cell 
monolayers. Cells were washed with phosphate-buffered saline (PBS), 
counted, and resuspended at 1.5 x 107 per ml in cytomix (120 mM KCl, 
0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4 [pH 7.6], 25 mM HEPES, 2 mM 
EGTA, 5 mM MgCl2; final pH of 7.6, adjusted with KOH) (80) containing 2 
mM ATP and 5 mM glutathione. Ten micrograms of in vitro-transcribed RNA 
was mixed with 400 l of the cell suspension. Cells were then 
electroporated, immediately transferred to 10 ml of culture medium, and 
seeded in a 10-cm dish. Electroporation conditions were 975 F and 270 V, 
using a Gene Pulser Xcell system (Bio-Rad, Munich, Germany) and a cuvette 
with a gap width of 0.4 cm (Bio-Rad) were used. Supernatants of the 
electroporated cells were harvested 72 h postelectroporation, cleared by 
passing them through 45-m-pore-size filters, and stored at -80°C. 
For the determination of viral titers, Huh7/Scr cells were seeded at a 
concentration of 4 x 104 per well in a 96-well plate in a total volume of 200 
l. Twenty-four hours later, serial dilutions of virus containing supernatant 
were added (6 wells per dilution). Three days later, cells were washed with 
PBS and fixed for 20 min with ice-cold methanol at -20°C. After three 
washes with PBS, NS5A was detected with a 1:2,000 dilution of mouse anti-
NS5A antibody 9E10 (kindly provided by C. Rice, The Rockefeller University, 
NY) in PBS supplemented with 5% bovine serum albumin (BSA) for 1 h at 
room temperature. Cells were washed again three times with PBS, and the 
bound primary antibodies were detected by incubation in PBS plus 5% BSA 
with goat anti-mouse IgG peroxidase-conjugated antibody (Sigma-Aldrich, 
St. Louis, MO) at a 1:400 dilution. After 1 h of incubation at room 
temperature, cells were washed three times with PBS; the Vector NovaRED 
substrate kit (Linaris Biologische Produkte GmbH, Wertheim, Germany) was 
used for detection of peroxidase. Virus titers (50% tissue culture infective 
dose [TCID50] per milliliter) were calculated based on the method described 
by Spearman (81) and Kärber (82). 
Preparation of HCVpp and VSV-Gpp. HIV-based pseudoparticles 
bearing HCV and VSV-G glycoproteins (HCVpp and VSV-Gpp) were 
generated by calcium phosphate cotransfection of 293T cells. Briefly, 3.6 x 
106 293T cells were seeded in 10-cm dishes 1 day before transfection with 
equal amounts of pTN7-Stopp plasmid and pcDNA3.1-ΔcE1E2-J6CH or 
pVPack-VSV-G (Agilent Technologies, Santa Clara, CA) for HCVpp or VSV-
Gpp, respectively. A total amount of 20 g of DNA was mixed with a 2 M 
CaCl2 solution and then 2x HEPES-buffered saline (HBS) was added 
dropwise to form a precipitate which was added to the cells. The medium 
was replaced the following day and supernatants containing the 
pseudoparticles were harvested 48 h later, cleared by passage through 
0.45-m-pore-size filters, and used for luciferase infection assays. 
Luciferase infection assays. For standard infection assays. 
Huh7/Scr cells were seeded at a density of 4 x 104/well in 96-well plates. 
One day later, cells were preincubated for 1 h at 37°C with the pertinent 
compounds and then inoculated with the virus and the compounds for 4 h at 
37°C. HCVpp were left for 6 instead of 4 h. Finally, virus-containing medium 
was replaced with a fresh medium-compound mixture. Luciferase activity 
was assayed 72 h postinfection. Cells were washed with PBS, lysed in 150 l 
of passive lysis buffer, and frozen. Upon thawing, lysates were resuspended 
by pipetting and 50 l was mixed with 25 l of a luciferin solution and 
measured in a luminometer for 2 s. The luciferin solution was LARII for 
Firefly luciferase assays and Stop&Glo reagent (Promega) for Renilla 
luciferase assays. The BioLux Gaussia luciferase assay kit (Promega) was 
used to assess Gaussia luciferase activity according to the manufacturer’s 
instructions. Cytotoxicity (viability) was measured in all infection assays 
using the CytoTox-Glo cytotoxicity assay (Promega) as described by the 
manufacturer with a FLUOstar OPTIMA plate luminometer (BMG LABTECH) 
according to the manufacturer’s instructions. The multiplicity of infection 
(MOI) used in the infections was 0.01 to 0.03 TCID50/cell. Unless otherwise 
stated, results for both infectivity and viability are the means (standard 
errors of the means [±SEM]; n 4) from two replicate infections measured in 
duplicate and expressed as relative light units (RLU) compared to those 
obtained in the infection of control (mock) cells. 
Attachment assay and qRT-PCR. Huh7/Scr cells were seeded in 
24-well plates at 1.5  105/well. The following day, cells were set on ice for 
30 min to cool down and then incubated with prechilled Jc1 HCVcc (at an 
MOI of 10 TCID50/cell) in the presence or absence of compounds for 2 h at 
4°C. Cells were washed 3 times with ice-cold PBS and lysed, and RNA was 
extracted using the Nucleo Spin RNA II kit (Macherey-Nagel, Düren, 
Germany) by following the manufacturer’s protocol. RNA concentration was 
determined by measurement of the optical density at 260 nm. Twenty-five 
micrograms of the total RNA sample was used for quantitative PCR analysis 
using a 7500 real-time PCR sequence detector system (Applied Biosystems, 
Waltham, MA). HCV-specific qRT-PCRs were conducted in duplicate for each 
sample with the OneStep RT-PCR kit (Qiagen, Hilden, Germany) using the 
following HCV 5’ untranslated region (UTR)-specific probe S-29 (5’-6-
carboxyfluorescein-CCTGATAGGGTGCTTGCGAGTGCC-tetrachloro-6-
carboxyfluorescein-3’) and primers S-271 (5’-GCGAAAGGCCTTGTGGTACT-
3’) and A-337 (5’-CACGGTC TACGAGACCTCCC-3’) (Biomers, Ulm, 
Germany). Reactions were performed in three stages by using the following 
conditions: stage 1, 60 min at 55°C (reverse transcription); stage 2, 15 min 
at 95°C (heat inactivation of reverse transcriptase and activation of Taq 
polymerase); and stage 3, 40 cycles of 15 s at 95°C and 1 min at 60°C 
(amplification). The total volume of the reaction mixture was 15 l, and it 
contained the following components: 2.66 M 6-carboxy-X-rhodamine 
(passive reference), 4 mM MgCl2, 0.66 mM deoxynucleoside triphosphates, 
0.266 M HCV probe, 1 M each HCV primer, and 0.6 l of enzyme mix. The 
amount of HCV RNA was calculated by comparison to serially diluted in vitro 
transcripts. 
Subgenomic replicon assay. Huh7/Scr cells were seeded in 24-well 
plates at 1.5 x 105/well. The following day, cells were preincubated for 1 h 
at 37°C with the pertinent compounds (lipoquads or telaprevir [VX-950], 
the latter has been purchased by Selleck Chemicals, Houston, TX) and then 
transfected with subgenomic replicon RNA using the Lipofectamine 2000 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. Four hours posttransfection, Lipofectamine-RNA-containing 
medium was replaced with a fresh medium-compound mixture and Firefly 
luciferase activity was measured 24 h later as described above. 
Cell-to-cell transmission assays. The first day, Huh7/Scr cells 
were infected with Jc1 HCVcc at an MOI of 10 TCID50/cell. These cells were 
then used as HCV donor cells, while Huh7.5-EGFP-NLS-IPS cells were used 
as acceptor cells. The latter cells stably express a chimeric protein that 
encompasses the enhanced green fluorescent protein (EGFP) associated 
with the simian virus 40 (SV40) nuclear localization sequence (NLS) 
followed by the mitochondrially tethered interferon beta promoter 
stimulator protein 1(IPS-1; all together, EGFP-NLS-IPS), which upon HCV 
infection is redistributed from mitochondria to the nucleus (35, 36). The 
following day, a 1:1 ratio of donor to acceptor cells was used and a total of 
2 x 105 cells/well were plated on 24-well chambered coverglasses with a 
medium containing lipoquads or dasatinib that inhibits HCV cell-to-cell 
spread (21), lipoquad buffer (0.1% vol/vol), or dimethyl sulfoxide (DMSO; 
0.1% [vol/vol]). Cells were covered with fresh medium containing 1% low-
melting-temperature agarose and compounds 4 h after seeding and further 
cultured for 20 h. Finally, cells were fixed with 4% paraformaldehyde and 
stained with anti-NS5A antibodies. Cell-to-cell spread was analyzed in a 
Leica TCS-SP5 confocal microscope. Quantification of Huh7.5/EGFP-NLS-IPS 
cells was done in 3 independent wells by taking 3 independent pictures of 
different fields of each well that contained at least 200 cells in total. Data 
are expressed as percentages in relation to lipoquad solvent-treated (for 
lipoquads) or DMSO-treated (for dasatinib) cells and represent mean values 
of the 3 independent fields of three biological replicates (±SEM). 
Patients and tissue explants. Surgically resected specimens of 
colorectal tissue were collected at St. Mary’s Hospital, Imperial College 
London, UK. All tissues were collected after receiving signed informed 
consent from all patients and under protocols approved by the Local 
Research Ethics Committee. The tissue was obtained from patients 
undergoing rectocele repair and colectomy for colorectal cancer. Only 
healthy tissue that was 10 to 15 cm away from any tumor was used. All 
patients were HIV and HCV negative. On arrival in the laboratory, resected 
tissue was cut into 2- to 3-mm3 explants comprising both epithelial and 
muscularis mucosae as described previously (38). Colorectal explants were 
maintained with DMEM containing 10% fetal calf serum, 2 mM L-glutamine, 
and antibiotics (100 U of penicillin/ml, 100 g of streptomycin/ml, and 80 
g of gentamicin/ml) at 37°C in an atmosphere containing 5% CO2. 
Tissue inhibition assays. Tissue explants were incubated with 
lipoquads or DAA (sofosbuvir [SOF] and ledipasvir [LDV], both at a 1 M 
final concentration; SOF and LDV have been purchased by Selleck 
Chemicals, Houston, TX) for 1 h prior to virus addition for 2 h. Explants 
were then washed 4 times with PBS to remove unbound virus and drug, 
transferred on gel foam rafts (Welbeck Pharmaceuticals, UK), and cultured 
in complete medium in the presence (sustained) or absence (pulse) of drug 
for 48 h at 37°C. Viral levels were measured by Gaussia luciferase 
quantification (Promega, Madison, WI) in a Synergy HT multidetection 
microplate reader (BioTek Instruments, Inc., Burlington, VT) as described 
above. 
Statistical and mathematical analysis. Statistical comparison 
between two groups was made by an unpaired t test. Statistically significant 
differences are shown in figures as follows: *, P < 0.05; **, P < 0.01; and 
***, P < 0.001. IC50s were calculated from sigmoid curve fitting (GraphPad 
Prism; GraphPad Software, La Jolla, CA) fulfilling the criterion of R2 >0.7. 
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